PML: underdiagnosed in MS patients on natalizumab.
Steiner
Israel
I
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018450:Disease Progression; D042241:Early Diagnosis; D005060:Europe / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015994:Incidence; D007968:Leukoencephalopathy, Progressive Multifocal / Q000175:diagnosis* / Q000453:epidemiology; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D000069442:Natalizumab; D012196:Review Literature as Topic; D014481:United States / Q000453:epidemiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab